Access. Assistance. Along the Journey.

Exelixis Access Services® (EASE) provides a variety of support to help your patients get started on treatment as soon as possible. EASE can meet the unique needs of your patients and practice at each step along the access journey.

HELP YOUR PATIENTS GET STARTED ON CABOMETYX® (cabozantinib)

Your EASE Case Manager

Case Manager

EASE offers regionally dedicated Case Managers as a single point of contact.

  • Can provide the status of your patient's access journey
  • Offers prompt support with payer coverage, financial assistance, and treatment coordination
  • Provides proactive follow-up

 

Get to know your EASE Case Manager
Call for EASE Support
CALL: 1-844-900-EASE
(1-844-900-3273)
Monday to Friday, 8:00 AM to 8:00 PM ET

Enroll your eligible patients in one of two ways

Option 1

Complete and submit the EASE enrollment form available on this page.

EASE enrollment

EASE Enrollment Form, including the 15-Day Free Trial Program, EASE Quick Start Program, EASE Co-Pay Program, and the EASE Patient Assistance Program (PAP)

Download the form
enrollment consent

Download the EASE Patient Authorization Form to obtain consent for enrollment in EASE programs

Download the form

 

Option 2

Cover My Meds

Access and submit a prior authorization request for CABOMETYX through CoverMyMeds®. Enroll eligible patients in EASE services at the same time. Click on the link to the right to access the online tool.

Enroll your eligible patients in EASE through CoverMyMeds

Get Started Now

PROGRAMS TO HELP PATIENTS START AND STAY ON CABOMETYX

15 Day Free Trial Program
15-Day Free Trial Program

Provides free drug to help patients start treatment quickly.*

 

CABOMETYX Quick Start Program
CABOMETYX Quick Start Program*

Provides free drug to eligible patients who experience a payer decision delay of 5 days or more.*

CABOMETYX EASE Copay Program
EASE $0 Co-Pay Program

Eligible commercially insured patients pay $0 per month, for a maximum benefit of $25,000 per year.

EASE Dose Exchange Program
Dose Exchange Program

Provides a free 15-tablet supply in the lower dose to help patients who require a dose reduction.

EASE Patient Assistance Program
EASE Patient Assistance Program (PAP)

Eligible patients who cannot afford their drug costs may receive CABOMETYX free of charge.

 

consent

15-Day Free Trial Program provides free drug to help patients start treatment quickly

Download the form
copay

EASE $0 Co-Pay Program

Enroll eligible patients
Dosing

EASE Dose Exchange Form to support patients who require a dose reduction

Download the form

SUPPORT FOR COVERAGE DETERMINATION

At your request, EASE can provide support with:

EASE Support Coverage
  • Benefits investigation
  • Prior authorization (PA) assistance
  • Appeals support and follow-up

*Limited to on-label indications. Additional restrictions and eligibility rules apply.
Additional restrictions and eligibility rules apply.

This description of the Exelixis Access Services® (EASE) program is for informational purposes only. Exelixis* makes no representation or guarantee concerning reimbursement or coverage for any service or item. Information provided through the Exelixis Access Services program does not constitute medical or legal advice and is not intended to be a substitute for a consultation with a licensed healthcare provider, legal counsel, or applicable third-party payer(s). Exelixis reserves the right to modify the program at any time without notice.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) support the use of cabozantinib (CABOMETYX) in the treatment of both aRCC and HCC

National Comprehensive Cancer Network® (NCCN®)

Kidney
FIRST- AND SECOND-LINE CLEAR CELL aRCC RECOMMENDATIONS

 

NCCN Preferred

1 L

Cabozantinib (CABOMETYX) is THE ONLY NCCN "PREFERRED" SINGLE-AGENT TKI option for 1L intermediate/poor risk clear cell aRCC1

2 L

Cabozantinib (CABOMETYX) is THE ONLY NCCN "PREFERRED" SINGLE-AGENT TKI option for 2L clear cell aRCC1

As defined by the NCCN Guidelines®, preferred interventions are based on superior efficacy, safety, and evidence; and when appropriate, affordability.

 
Liver
SECOND-LINE HCC RECOMMENDATION

NCCN Category 1 Cabozantinib (CABOMETYX) is RECOMMENDED AS A CATEGORY 1, SUBSEQUENT-LINE TREATMENT OPTION FOR HCC, following disease progression (Child-Pugh A)2*

*Data reflect use after sorafenib. Lenvatinib is recommended by the NCCN as a first-line systemic therapy option, but there are no data to define optimal treatment for those who progress on lenvatinib.2

Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

aRCC=advanced renal cell carcinoma; HCC=hepatocellular carcinoma; TKI=tyrosine kinase inhibitor.

 

INDICATIONS

CABOMETYX® (cabozantinib) is indicated for the treatment of patients with advanced renal cell carcinoma (RCC).

CABOMETYX® (cabozantinib) is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Hemorrhage: Severe and fatal hemorrhages occurred with CABOMETYX. The incidence of Grade 3 to 5 hemorrhagic events was 5% in CABOMETYX patients. Discontinue CABOMETYX for Grade 3 or 4 hemorrhage. Do not administer CABOMETYX to patients who have a recent history of hemorrhage, including hemoptysis, hematemesis, or melena.

Perforations and Fistulas: GastrointestinaI (GI) perforations, including fatal cases, occurred in 1% of CABOMETYX patients. Fistulas, including fatal cases, occurred in 1% of CABOMETYX patients. Monitor patients for signs and symptoms of perforations and fistulas, including abscess and sepsis. Discontinue CABOMETYX in patients who experience a fistula that cannot be appropriately managed or a GI perforation.

Thrombotic Events: CABOMETYX increased the risk of thrombotic events. Venous thromboembolism occurred in 7% (including 4% pulmonary embolism) and arterial thromboembolism in 2% of CABOMETYX patients. Fatal thrombotic events occurred in CABOMETYX patients. Discontinue CABOMETYX in patients who develop an acute myocardial infarction or serious arterial or venous thromboembolic event requiring medical intervention.

Hypertension and Hypertensive Crisis: CABOMETYX can cause hypertension, including hypertensive crisis. Hypertension occurred in 36% (17% Grade 3 and <1% Grade 4) of CABOMETYX patients. Do not initiate CABOMETYX in patients with uncontrolled hypertension. Monitor blood pressure regularly during CABOMETYX treatment. Withhold CABOMETYX for hypertension that is not adequately controlled with medical management; when controlled, resume at a reduced dose. Discontinue CABOMETYX for severe hypertension that cannot be controlled with anti-hypertensive therapy or for hypertensive crisis.

Diarrhea: Diarrhea occurred in 63% of CABOMETYX patients. Grade 3 diarrhea occurred in 11% of CABOMETYX patients. Withhold CABOMETYX until improvement to Grade 1 and resume at a reduced dose for intolerable Grade 2 diarrhea, Grade 3 diarrhea that cannot be managed with standard antidiarrheal treatments, or Grade 4 diarrhea.

Palmar-Plantar Erythrodysesthesia (PPE): PPE occurred in 44% of CABOMETYX patients. Grade 3 PPE occurred in 13% of CABOMETYX patients. Withhold CABOMETYX until improvement to Grade 1 and resume at a reduced dose for intolerable Grade 2 PPE or Grade 3 PPE.

Proteinuria: Proteinuria occurred in 7% of CABOMETYX patients. Monitor urine protein regularly during CABOMETYX treatment. Discontinue CABOMETYX in patients who develop nephrotic syndrome.

Osteonecrosis of the Jaw (ONJ): ONJ occurred in <1% of CABOMETYX patients. ONJ can manifest as jaw pain, osteomyelitis, osteitis, bone erosion, tooth or periodontal infection, toothache, gingival ulceration or erosion, persistent jaw pain, or slow healing of the mouth or jaw after dental surgery. Perform an oral examination prior to CABOMETYX initiation and periodically during treatment. Advise patients regarding good oral hygiene practices. Withhold CABOMETYX for at least 28 days prior to scheduled dental surgery or invasive dental procedures. Withhold CABOMETYX for development of ONJ until complete resolution.

Wound Complications: Wound complications were reported with CABOMETYX. Stop CABOMETYX at least 28 days prior to scheduled surgery. Resume CABOMETYX after surgery based on clinical judgment of adequate wound healing. Withhold CABOMETYX in patients with dehiscence or wound healing complications requiring medical intervention.

Reversible Posterior Leukoencephalopathy Syndrome (RPLS): RPLS, a syndrome of subcortical vasogenic edema diagnosed by characteristic finding on MRI, can occur with CABOMETYX. Evaluate for RPLS in patients presenting with seizures, headache, visual disturbances, confusion, or altered mental function. Discontinue CABOMETYX in patients who develop RPLS.

Embryo-Fetal Toxicity: CABOMETYX can cause fetal harm. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Verify the pregnancy status of females of reproductive potential prior to initiating CABOMETYX and advise them to use effective contraception during treatment and for 4 months after the last dose.

ADVERSE REACTIONS

The most commonly reported (≥25%) adverse reactions are: diarrhea, fatigue, decreased appetite, PPE, nausea, hypertension, and vomiting.

DRUG INTERACTIONS

Strong CYP3A4 Inhibitors: If coadministration with strong CYP3A4 inhibitors cannot be avoided, reduce the CABOMETYX dosage. Avoid grapefruit or grapefruit juice.

Strong CYP3A4 Inducers: If coadministration with strong CYP3A4 inducers cannot be avoided, increase the CABOMETYX dosage. Avoid St. John’s wort.

USE IN SPECIFIC POPULATIONS

Lactation: Advise women not to breastfeed during CABOMETYX treatment and for 4 months after the final dose.

Hepatic Impairment: In patients with moderate hepatic impairment, reduce the CABOMETYX dosage. CABOMETYX is not recommended for use in patients with severe hepatic impairment.

Please see accompanying full Prescribing Information.

References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Kidney Cancer V.2.2020. ©National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed August 14, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hepatobiliary Cancers V.3.2019. ©National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed August 14, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org.

CABOMETYX now #1 TKI in new prescriptions for aRCC